Search company, investor...



Other Investors | Alive

About Neorphys

Neorphys is a specialty pharma company focusing on safe pain relief, especially visceral pain management.

Headquarters Location

UFR Medecine Caremeau Avenue Kennedy, CS 83021



Missing: Neorphys's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Neorphys's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Neorphys Patents

Neorphys has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Acute pain, Analgesics, Morphinans, Phenols, Psychiatric diagnosis


Application Date


Grant Date



Related Topics

Acute pain, Analgesics, Morphinans, Phenols, Psychiatric diagnosis



Neorphys Frequently Asked Questions (FAQ)

  • What is Neorphys's latest funding round?

    Neorphys's latest funding round is Other Investors.

  • Who are the investors of Neorphys?

    Investors of Neorphys include Soridec and Inserm Transfert.

  • Who are Neorphys's competitors?

    Competitors of Neorphys include Zyla Life Sciences, Annovis Bio, Afferent Pharmaceuticals, Adolor Corporation, ZARS and 12 more.

Compare Neorphys to Competitors


Ameritox is the nation's leader in pain prescription monitoring.

TheraQuest Biosciences

TheraQuest Biosciences, Inc. is building a diversified portfolio of pharmaceutical products to address pain management.

Xanodyne Pharmaceuticals

Xanodyne Pharmaceuticalsis a speciality pharmaceutical company focused on products for women's health care and pain management.


Neurotide is developing pain killers based on the body's own natural pain killer, endomorphin. Synthesised endomorphin can relieve pain when delivered directly to the brain, but has a short life span and is unsuitable as a drug without modifications. Neurotide is developing an orally available form of endomorphin for the treatment of chronic and acute pain as well as a new treatment for neuropathic pain, which can be caused by diabetes, injury and certain infections.

Emagin Therapeutics

Emagin Therapeutics develops new and improved drug entities to treat acute, chronic and cancer-related pain and delivery systems for pain management.

Intranasal Therapeutics

Intranasal Therapeutics, founded in 1998 by Edwin Cohen, founder and former Chairman and CEO of Barr Laboratories, Intranasal Therapeutics, Inc. (ITI) is a specialty pharmaceutical company focused on developing nasally delivered pharmaceutical products, with a particular focus on drugs treating pain and disorders related to the central nervous system.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.